The Oncotype DX® Breast Recurrence Score™ Result Changes Physicians’ Treatment Decisions

The Oncotype DX Breast Recurrence Score reveals the underlying biology that changes treatment decisions in more than 30% of patients in 14 independent studies across 10 countries*1-10

  • After receiving the Breast Recurrence Score result, physicians and their patients changed treatment decisions, even when they already had made definitive treatment decisions11
    • 33% of the overall population switched from chemotherapy plus hormonal therapy to hormonal therapy alone based on a low Breast Recurrence Score result12
    • 4% of the overall population switched from hormonal therapy only to chemotherapy plus hormonal therapy based on a high Breast Recurrence Score result12

Studies have shown that Breast Recurrence Score results reduce chemotherapy use, spare patients the negative health and quality-of-life impact of unnecessary chemotherapy, and reduce the costs to society and the healthcare system.11-15

Dr. John Shook, Medical Director at St. Luke's Health System Comprehensive Breast Program in Kansas City, recounts two examples of how a patient's treatment decision was altered based the utilization of a genomic test, such as the Breast Recurrence Score.


*Range – 24.5%-66%


1. Geffen et al. Ann Oncol. 2011.
2. Albanell et al. Ann Oncol. 2012.
3. Davidson et al. Eur J Cancer. 2013.
4. Gligorov et al. ASCO 2012.
5. Eiermann et al. Ann Oncol. 2013.
6. de Boer et al. Med J Aust. 2013.
7. Holt et al. Br J Cancer. 2013.
8. Yamauchi et al. ESMO 2011.
9. Bargallo et al. ESMO 2012.
10. Oratz et al. J Oncol Pract. 2011.
11. Hornberger et al. J Natl Cancer Inst. 2012.
12. Hornberger et al. St Gallen 2011.
13. Lo et al. J Clin Oncol. 2010.
14. Hornberger et al. Am J Manag Care. 2005.
15. Hornberger et al. J Oncol Pract. 2011.


Next: Beyond Traditional Factors